1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,744 | 0,804 | 08.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tevogen Bio Inc: Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy | 1 | GlobeNewswire (USA) | ||
| Mi | Tevogen: Institutioneller Anteilsbesitz steigt um 60 % im ersten Quartal 2025 | 1 | Investing.com Deutsch | ||
| Mi | Tevogen reports 60% rise in institutional ownership in Q1 2025 | 1 | Investing.com | ||
| Di | Tevogen.AI expands AI collaboration with Microsoft, Databricks for oncology | 5 | Investing.com | ||
| Di | Tevogen Bio Inc: Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology | 80 | GlobeNewswire (Europe) | Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 01.08. | Tevogen Bio Inc: Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders | 122 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen... ► Artikel lesen | |
| 01.08. | Fördermittel für KI-Plattform: Aktie von Tevogen Bio legt zu | - | Investing.com Deutsch | ||
| 01.08. | Tevogen Bio stock rises amid $1 million grant funding | 2 | Investing.com | ||
| 01.08. | Tevogen Bio Inc: Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion | 80 | GlobeNewswire (Europe) | Funds will support advancement of Tevogen.AI, the Company's artificial intelligence-driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non-dilutive... ► Artikel lesen | |
| 30.07. | Tevogen executives and directors own over 74% of company stock | 2 | Investing.com | ||
| 30.07. | Tevogen Bio Inc: Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision | 181 | GlobeNewswire (Europe) | WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common... ► Artikel lesen | |
| 28.07. | Tevogen Bio Inc: Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare | 3 | GlobeNewswire (USA) | ||
| 18.07. | WIPO veröffentlicht Patent von Tevogen Bio für KI-gestützte Peptid-Vorhersage | 4 | Investing.com Deutsch | ||
| 18.07. | Tevogen Bio's AI-powered peptide prediction patent published by WIPO | 1 | Investing.com | ||
| 18.07. | Tevogen Bio Inc: Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides | 129 | GlobeNewswire (Europe) | WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization... ► Artikel lesen | |
| 17.07. | Tevogen Bio Inc: Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility | 1 | GlobeNewswire (USA) | ||
| 16.07. | Tevogen Bio Inc: Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch | 1 | GlobeNewswire (USA) | ||
| 14.07. | Tevogen Bio Inc: Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs | 149 | GlobeNewswire (Europe) | Tevogen.AI's model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing... ► Artikel lesen | |
| 10.07. | Tevogen Bio Inc: Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation | 308 | GlobeNewswire (Europe) | CEO's personal contribution fully funds build-out and first-year operationsDoubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI... ► Artikel lesen | |
| 10.07. | Tevogen Bio Holdings stattet CEO mit 8 Millionen Restricted Shares aus und aktualisiert Aktienanzahl | 4 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
101 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| AMGEN | 247,20 | -0,14 % | Amgen hebt Prognose nach überraschend gut verlaufenem Quartal an | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt nach einem überraschend gut gelaufenen Quartal optimistischer auf 2025. Der Umsatz dürfte bei 35 bis 36 Milliarden US-Dollar liegen, teilte... ► Artikel lesen | |
| NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,250 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
| REGENERON PHARMACEUTICALS | 485,60 | +0,43 % | Regeneron Pharmaceuticals declares $0.88 dividend | ||
| INOVIO PHARMACEUTICALS | 1,210 | 0,00 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem ends French lab operations, loses deal | ||
| COSCIENS BIOPHARMA | 2,900 | -5,84 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,410 | +0,35 % | Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 | WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its second quarter that Increases, from last yearThe company's earnings totaled $240.53 million, or $1.23 per... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,426 | -1,62 % | Weltweites Biotech-Finale: NurExone unter den besten 25 | ||
| ARROWHEAD PHARMACEUTICALS | 13,995 | -0,74 % | Arrowhead Pharma: Leerink Partners senkt Kursziel auf 21 US-Dollar | ||
| XOMA ROYALTY | 22,600 | -0,88 % | XOMA Royalty Corporation Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,250 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds | King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,780 Euro und damit +0,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.